About the Editors
Cosimo De Nunzio, MD, PhD, Italy
Cosimo De Nunzio, MD, PhD, is Associate Professor of Urology at the Department of Molecular and Clinical Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Italy. He is also Consultant Urologist in the Division of Urology at Ospedale Sant’Andrea, Roma where he holds a highly specialized position in Uro-Oncology. He has served on numerous National guideline panels for prostatic diseases and chaired the European Association of Urology, Young Academic Urologists BPH group.
Prof De Nunzio’s clinical area of expertise focuses on urological diseases, particularly benign prostatic hyperplasia, voiding dysfunction, prostate cancer and minimally invasive surgery. His research interests particularly include investigations on the role of lifestyle, metabolic syndrome, inflammation in prostatic diseases development and progression, new non-invasive imaging modalities for the diagnosis of prostatic diseases as well as on new minimally invasive treatments for men with voiding dysfunction and benign prostatic obstruction.
Prof. De Nunzio has participated in over 300 published studies, and his research has appeared multiple times in European Urology, the Journal of Urology, Prostate Cancer and Prostatic diseases, BJUI, among many others.
In addition to contributing original research, Prof De Nunzio is an active reviewer for more than 25 peer-reviewed journals. He sits on the editorial board for European Urology Focus, BMC Urology, Minerva Urology and Nephrology, Urology Video Journal and serves as a consulting editor for European Urology. From January 2022 he will serve Editor-in-Chief for Prostate Cancer and Prostatic Disease.
Prof De Nunzio earned his medical degree from the Sapienza University of Rome and continued his training with a residency in Urology and a PhD in Advanced Surgical technologies at the Sapienza University of Rome. He completed his fellowship at the Freeman Hospital, University of Newcastle upon Tyne, at the Royal Hallamshire Hospital (UK) and at the Henry Mondor University Hospital, Paris (France). He was also selected for the EAU/AUA exchange programme.
Dr. Luca Cindolo, MD and PhD, is an italian urologist, who has focussed his professional life in urooncology on clinical, surgical and biological areas, and in lower urinary tract dysfunction, with attention to the surgical relief of the bladder output obstruction.
With his >240 peer rewiewed papers published, in the last 2 decades he participated as principal investigator and coinvestigator in several clinical trials. After a long period in the National Health system, where he reached the position of Chief of the Robotic Unit of “SS. Annunziata” Hospital in Chieti , he is currently the Chief of the Urology Dept. of the Villa Stuart Private Hospital in Rome and cofounder of the “Centro Urologico Europeo” (CURE Group).
He has served in multiple roles with the Italian Urological Society (SIU) and is currently an active member of the Research Office of the same society. He also serves as reviewer in several peer reviewed journals (e.g. European Urology, Urology, Int Journal of Urology and Nephrology, Minerva Urology and Nephrology, Urology Annals, PLoS One).
His principal research interests recently lie with minimally invasive surgical treatments for benign prostatic hyperplasia and pharmacological therapy of prostate cancer. He is also active in medical education and is the coordinator of periodic medical writing courses.
He is a medical graduate of the University of Naples IT, continued his training with a residency in Urology in University of Naples IT. He was trained in urological surgery through several the training programmes across Europe (France, Germany, Spain). He concluded a PhD programme in Translational Medicine at the University of Chieti, IT.
Timothy J. Daskivich, MD, MSHPM is an Assistant Professor and Director of Health Services Research in the Department of Surgery/Division of Urology at Cedars-Sinai Medical Center. He graduated magna cum laude in Biochemical Sciences from Harvard College in 2001 and earned his MD from Harvard Medical School in 2006. He then completed residency in Urology at UCLA in 2012 and did a combined health services research and urologic oncology fellowship with the Robert Wood Johnson Clinical Scholars Program and Institute of Urologic Oncology at UCLA. Dr. Daskivich’s clinical practice includes comprehensive management of all genitourinary malignancies, including open, laparoscopic, and robotic approaches, with a focus on robotic and focal therapy for prostate cancer. His main research interest seeks to elucidate the roles of age, comorbidity, and life expectancy in risk stratification and decision making for men with prostate cancer. He also conducts investigator-initiated trials involving prostate PET MRI imaging and using activity monitors to assess postoperative ambulation in men undergoing major surgery. He won the AUA/Urology Care Foundation Astellas Rising Stars in Urology Research award in 2018 for his NIH/NCI-funded K08 career development award, which involves development of a patient-centered approach to improve the quality of communication of prognosis and life expectancy to patients during prostate cancer treatment counseling discussions. He has been funded by the NCI/NIH, Department of Defense, American Cancer Society, and American Urological Association.
Tanya Barauskas Dorff, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research and serves as head of the genitourinary cancers program at City of Hope. She is an internationally recognized leader in prostate cancer, serving on the NCCN guidelines panel for prostate cancer as well as being co-chair of the SWOG Prostate Cancer committee. After graduating from UCLA medical school and residency at Mount Sinai, she completed her hematology-oncology fellowship training at LAC-USC Medical Center, later serving as faculty at the USC Norris Comprehensive Cancer Center prior to joining City of Hope.
Dr. Dorff’s research interests in prostate cancer are focused on novel immunotherapy and immunomodulatory strategies. With the support of the Prostate Cancer Foundation she is leading a trial of a novel PSCA targeted chimeric antigen receptor (CAR) T cell developed at City of Hope, and is working with Dr. Priceman and the SPORE with UCLA to further advance this powerful technology for the treatment of prostate cancer. She also has federal and foundation funding for projects studying early PARP inhibition in diverse prostate cancer patients, ctDNA as a tool in understanding cancer evolution, and development of a novel radiopharmaceutical.
Dr. Dorff has published over 90 original research mansuscripts along with more than 50 review articles and editorials in top-tier journals, including Cancer, Lancet Oncology and Journal of Clinical Oncology. She serves a key role in several multi-center trials of immunotherapy including other CAR T constructs and T cell engaging antibodies. She has been invited to speak at multiple national and international meetings about her research.
Jack A Schalken
Jack A Schalken PhD (1959) has an appointment as professor of experimental urology at Radboud Institute for Molecular Life Sciences, Nijmegen, NL. Dr Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was (co) appointed as professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud Institute for Molecular Life Sciences (Nijmegen). His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes:
- Unravelling the mechanism of (GU) cancer invasion/cadherin switching/EMT
- Cancer stem/initiating cells
- Targeted therapy in (GU) cancer
- Molecular diagnostics of prostate cancer (eg PCA3, SelectMDx)
- Combining 1 through 4 to make steps towards precision medicine
Dr Schalken is member of 12 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as ESUR, SBUR, EAU, ASCO and ESMO. Dr Schalken was co-founder and CSO of NovioGendix BV, a biomarker company recently acquired by MDxHealth SA and Oncodrone BV, a biopharmaceutical company. Dr Schalken is (co)author on more than 340 peer reviewed publications, 81 book chapters and has edited 10 books/special journal issues. He supervised 34 completed PhD theses. He is inventor on approximately 20 patent applications (some still pending approval).
Inge van Oort
Dr. Inge van Oort is an oncological urologist at the Radboud University Nijmegen Medical Centre, the Netherlands and she is the chair of Uro-Oncology Cancers at the Center of Oncology Radboudumc. She earned her MD in 2006. She completed fellowship in oncological urology in 2008 and was appointed as an oncological urologist and senior staff member. In 2009, she obtained her PhD on the clinical relevance of pathological findings after radical prostatectomy at the Radboudumc.
Inge is a member of EAU Guideline Office- new media group and a member of Video Committee of the Scientific Congress Office. She is also member of the multidisciplinary Dutch guideline group on prostate cancer since 2012. On national level she has been part of several activities at the Dutch Urological Society(DUA). She was the chair of the working group on Oncological Urology (WOU) for 7 years and is member of the board of education for residents (CCO). Her main interest are urological oncology with a special focus on molecular markers and castration resistant prostate cancer. She has published more than 100 articles in peer-reviewed journals. She is principle investigator of several multicenter trials funded by the Dutch Cancer Society and ZonMw.
Andrew Armstrong, Durham, NC, USA
Mark Emberton, London, UK
Mauro Gacci, Firenze, Italy
Stavros Gravas, Cyprus, Greece
Michael Hofman, Melbourne, Australia
Steven Kaplan, New York, NY, USA
Stephan Madersbacher, Vienna, Austria
Anthony Chi Fai Ng, Hong Kong, China
Claus Georg Roehrborn, Dallas, TX, USA
Mohummad Minhaj Siddiqui, Baltimore, MD, USA
Henry H Woo, Sidney, Australia
Stephen J. Freedland, MD, USA
Stephen J. Freedland, MD, is director of the Center for Integrated Research in Cancer and Lifestyle and co-director of the Cancer Genetics and Prevention Program and Associate Director for Faculty Development at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute. He is also a faculty physician in the Division of Urology within the Department of Surgery at Cedars-Sinai. He has served on numerous American Urological Association guideline panels for prostate cancer and co-chaired a prostate cancer guideline panel for the American Society of Clinical Oncology.
Dr. Freedland's clinical area of expertise focuses on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. His approach toward cancer prevention and awareness focuses on treating the whole patient, not just the disease, by combining traditional Western medicine with complementary holistic interventions. His research interests include investigations on urological diseases and the role of diet, lifestyle and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer.
Dr. Freedland has participated in over 400 published studies, and his research has appeared multiple times in The Journal of the American Medical Association, Journal of the National Cancer Institute, Journal of Clinical Oncology, The Journal of Urology, Cancer Prevention Research, Cancer and BJUI, among many others.
In addition to contributing original research, Dr. Freedland is an active reviewer for more than 50 peer-reviewed journals. He sits on the editorial board for Cancer Prevention Research, European Urology, International Journal of Urology, Nature Reviews Urology and BJUI, and serves as editor-in-chief for Prostate Cancer and Prostatic Disease and as a consulting editor for European Urology.
Dr. Freedland earned his medical degree from the University of California, Davis, and continued his training with a residency in Urology at the UCLA Medical Center. He completed his fellowship in urological oncology at the Johns Hopkins Hospital. Before joining Cedars-Sinai, Dr. Freedland was at Duke University School of Medicine, where he specialized in surgical oncology and urologic oncology, and served as an associate professor with tenure in the Division of Urology, Department of Surgery and in the Department of Pathology.